UE2343   Click here for help

GtoPdb Ligand ID: 12037

Synonyms: compound 4 [PMID: 28012176] | UE-2343 | Xanamem®
Compound class: Synthetic organic
Comment: UE2343 is an oral, brain-penetrant hydroxysteroid 11-beta dehydrogenase 1 (11-βHSD1) inhibitor that was developed to reduce brain levels of the stress hormone cortisol, as a mechanism to improve memory in Alzheimer's disease patients [1-2]. It failed to provide efficacy in a phase 2 clinical trial.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 123.24
Molecular weight 381.13
XLogP 0.85
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(N1[C@@H]2CC[C@H]1CC(C2)(O)c1ncccn1)c1csc(c1)c1c[nH]nc1
Isomeric SMILES C1C[C@H]2CC(C[C@@H]1N2C(=O)c1csc(c1)c1c[nH]nc1)(c1ncccn1)O
InChI InChI=1S/C19H19N5O2S/c25-17(12-6-16(27-11-12)13-9-22-23-10-13)24-14-2-3-15(24)8-19(26,7-14)18-20-4-1-5-21-18/h1,4-6,9-11,14-15,26H,2-3,7-8H2,(H,22,23)/t14-,15+,19?
No information available.
Summary of Clinical Use Click here for help
UE2343 was advanced to clinical trial, to evaluate its potential efficacy in patients with mild Alzheimer's disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02727699 A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) Phase 2 Interventional Actinogen Medical The results from this study have been posted on ClinicalTrials.gov. UE2343 (Xanamen®) failed to show clinical benefit in patients with mild Alzheimer's dementia when compared to placebo.